Literature DB >> 19191641

Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study.

Denise Gravel1, Mark Miller, Andrew Simor, Geoffrey Taylor, Michael Gardam, Allison McGeer, James Hutchinson, Dorothy Moore, Sharon Kelly, David Boyd, Michael Mulvey.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is the most frequent cause of health care-associated infectious diarrhea in industrialized countries. The only previous report describing the incidence of health care-associated CDI (HA CDI) in Canada was conducted in 1997 by the Canadian Nosocomial Infection Surveillance Program. We re-examined the incidence of HA CDI with an emphasis on patient outcomes.
METHODS: A prospective surveillance was conducted from 1 November 2004 through 30 April 2005. Basic demographic data were collected, including age, sex, type of patient ward where the patient was hospitalized on the day HA CDI was identified, and patient comorbidities. Data regarding severe outcome were collected 30 days after the diagnosis of HA CDI; severe outcome was defined as an admission to the intensive care unit because of complications of CDI, colectomy due to CDI, and/or death attributable to CDI.
RESULTS: A total of 1430 adults with HA CDI were identified in 29 hospitals during the 6-month surveillance period. The overall incidence rate of HA CDI for adult patients admitted to these hospitals was 4.6 cases per 1000 patient admissions and 65 per 100,000 patient-days. At 30 days after onset of HA CDI, 233 patients (16.3%) had died from all causes; 31 deaths (2.2%) were a direct result of CDI, and 51 deaths (3.6%) were indirectly related to CDI, for a total attributable mortality rate of 5.7%.
CONCLUSIONS: The rates are remarkably similar to those found in our previous study; although we found wide variations in HA CDI among the participating hospitals. However, the attributable mortality increased almost 4-fold (5.7% vs. 1.5%; P<.001).

Entities:  

Mesh:

Year:  2009        PMID: 19191641     DOI: 10.1086/596703

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  95 in total

1.  Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection.

Authors:  Sahil Khanna; Arjun Gupta; Larry M Baddour; Darrell S Pardi
Journal:  Intern Emerg Med       Date:  2015-12-22       Impact factor: 3.397

2.  High Mortality Risk in Chronic Kidney Disease and End Stage Kidney Disease Patients with Clostridium Difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Parkpoom Phatharacharukul; Pailin Mahaparn; Jackrapong Bruminhent
Journal:  J Nat Sci       Date:  2015-04

Review 3.  Surgical Management of Clostridium difficile Colitis.

Authors:  Ann K Seltman
Journal:  Clin Colon Rectal Surg       Date:  2012-12

4.  Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Authors:  Daniel E Freedberg; Julian A Abrams
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

5.  Reducing the risk of severe complications among patients with Clostridium difficile infection.

Authors:  Kamran Manek; Victoria Williams; Sandra Callery; Nick Daneman
Journal:  Can J Gastroenterol       Date:  2011-07       Impact factor: 3.522

6.  Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study.

Authors:  I Vesteinsdottir; S Gudlaugsdottir; R Einarsdottir; E Kalaitzakis; O Sigurdardottir; E S Bjornsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-23       Impact factor: 3.267

7.  Association Between Use of Proton Pump Inhibitors and a Clostridium difficile-Associated Disease Outbreak: Case-Control Study.

Authors:  Stephanie Linney; Tania Fernandes; Thomas Einarson; Anjana Sengar; John H Walker; Allan Mills
Journal:  Can J Hosp Pharm       Date:  2010-01

8.  Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.

Authors:  Vladimir Beran; Dittmar Chmelar; Jana Vobejdova; Adela Konigova; Jakub Nemec; Josef Tvrdik
Journal:  Folia Microbiol (Praha)       Date:  2013-10-11       Impact factor: 2.099

Review 9.  A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.

Authors:  Emma Allen-Vercoe; Gregor Reid; Norman Viner; Gregory B Gloor; Susy Hota; Peter Kim; Christine Lee; Kieran O'Doherty; Stephen J Vanner; J Scott Weese; Elaine O Petrof
Journal:  Can J Gastroenterol       Date:  2012-07       Impact factor: 3.522

10.  Impact of malignancy on Clostridium difficile infection.

Authors:  M S Chung; J Kim; J O Kang; H Pai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.